Avadel Rings the Closing Bell
About This Event
Avadel Pharmaceuticals (Nasdaq: AVDL), a global biopharmaceutical company focused on transforming medicines to transform lives, visits the Nasdaq MarketSite in Times Square to ring the Closing Bell in celebration of their launch of LUMRYZTM, which was recently approved by the U.S. FDA as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. In honor of the occasion, Greg Divis, Avadel CEO, rings the Closing Bell accompanied by Katie, a person with narcolepsy, as well as renowned sleep specialists Dr. Anne Marie Morse and Dr. Thomas Stern.